Local Infusion

MYLOCALINFUSION.COM

CABENUVA (CABOTEGRAVIR EXTENDED-RELEASE INJECTABLE SUSPENSION; RILPIVIRINE EXTENDED-RELEASE INJECTABLE SUSPENSION) ORDER FORM

PATIENT INFORMATION

Patient Name: _____ DOB: _____

Mobile Number: _____ Patient Weight: _____kg

Allergies: _____

❑ New Start Therapy | ❑ Continuation of Therapy & Date of last dose (if applicable): _____

DIAGNOSIS (Provider must specify)

HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

❑ Human immunodeficiency virus (HIV) disease, ICD 10: B20._____

❑ Asymptomatic HIV infection status, ICD 10: z21._____

PROVIDER INFORMATION

Provider Name (print name): _____ Provider NPI:_____

Signature: _____ Date: _____

Contact Name: _____ Phone: _____ Fax: _____

Email Address: _____

Prerequisites to treatment – ensure the following information is complete and attached with referral:

❑ Demographics ❑ Labs and tests supporting diagnosis ❑ Office/progress notes

PRE-MEDICATION

Recommendations per PI are selected, these will be given to patient unless otherwise specified.

❑ Acetaminophen (Tylenol) 500 mg PO

❑ Benadryl 25mg PO

❑ Famotidine 20 mg IV

❑ Cetirizine (Zyrtec) 10 mg PO

❑ Methylprednisolone (Solu-Medrol) 125 mg IVP

❑ Other: _____ Dose: _____ Route: _____

CABENUVA (CABOTEGRAVIR EXTENDED-RELEASE INJECTABLE SUSPENSION; RILPIVIRINE EXTENDED-RELEASE INJECTABLE SUSPENSION) ORDER FORM

MEDICATION			
MEDICATION	**DOSE**	**ROUTE**	**FREQUENCY**
Cabenuva	❑ Monthly dosing: Initiate injections of CABENUVA (600 mg of abotegravir and 900 mg of rilpivirine) on the last day of current antiretroviral therapy or oral lead-in and continue with injections of CABENUVA (400 mg of cabotegravir and 600 mg of rilpivirine) every month thereafter.	Gluteal IM injection	❑ Every month ❑ Every 2 months
	❑ Bimonthly dosing: Initiate injections of CABENUVA (600 mg of cabotegravir and 900 mg of rilpivirine) on the last day of current antiretroviral therapy or oral lead-in for 2 consecutive months and continue with injections of CABENUVA every 2 months thereafter.		

LABS / SPECIAL INSTRUCTIONS